Benitec Reports 100% Response Among 9 Patients in BB-301 Results Announced in October
Key Facts
Benitec Biopharma announced on October 28, 2026, that all 9 patients treated with BB-301 met the company’s definition of a treatment responder, in results covering 6 patients in the low-dose group and 3 in the high-dose group. The announcement concerned interim trial results, not a new clinical development on November 13, the date of the news covered in this report. The data included 12 months of follow-up for all patients in the first cohort, while the first patient in the second cohort had reached 9 months of follow-up and the other two patients had reached 3 months. Chief Executive Officer Jerel Banks said the progressive loss of swallowing ability “severely affects patients with oculopharyngeal muscular dystrophy,” adding that “there are no approved therapies” to address this medical need. The results put the BB-301 program at the forefront of the company’s developments, while the study remains at an early stage and its regulatory path is still in progress.
Detailed measures show a mixed picture depending on the swallowing measure and dose group. At month 3 after treatment, 67% of patients in the first cohort and 100% of patients in the second cohort met the response criteria for improvement in pharyngeal clearance. In the functional swallowing test using the cold-water swallow test, the rates were 17% in the first cohort and 67% in the second cohort at the same follow-up point. These figures distinguish the company’s overall response from results on specific performance measures; the official responder rate does not mean improvement was equal across all tests or patients. The company said no serious adverse events had occurred among patients treated with BB-301 as of its October 28 statement, referring to the safety record reported through that date.
The trial includes 9 patients across the two groups described, a limited sample for interpreting interim results, and the available follow-up periods differ among participants. The study is being conducted as an open-label dose-escalation trial to assess BB-301’s safety and clinical activity in patients with oculopharyngeal muscular dystrophy and moderate dysphagia. The treatment is administered in intramuscular doses, while the reported results focus on changes related to swallowing function. The company describes BB-301 as a localized gene therapy designed to silence the mutated copy of the PABPN1 gene while enabling expression of a functional replacement copy. This mechanism remains in clinical development, and the current results are based on small cohorts with varying follow-up periods.
The first patient in the low-dose group had completed 24 months of follow-up, according to an earlier update issued on January 11, 2026. The company said at the time that improvements in pharyngeal residue and dysphagia symptoms persisted at month 24, with further improvement compared with the 12-month follow-up. This represents the longest follow-up the company has reported for one patient, but it is separate in time from the cohort of interim results released in October. BB-301 has also received orphan-drug designation from the European Medicines Agency, as well as orphan-drug and fast-track designations from the U.S. Food and Drug Administration. These regulatory designations do not mean the therapy has been approved.
On the regulatory front, Benitec said on October 5 that the FDA had requested additional data, including data from a company-sponsored natural history study of patients with oculopharyngeal muscular dystrophy, before confirming the final pivotal study design. The company set the first quarter of 2027 as the expected timing for confirming that design and said patient enrollment is scheduled to begin in mid-2027. These steps link the move from early-stage study results to a pivotal trial, while the announced timeline remains the company’s plan. In trading ahead of the news, BNTC shares closed at $9.09 on November 12, 2026. The available data here do not include a documented session low or high.